Key result
SAVR with RESILIA tissue shows excellent early safety with ~94% two-year survival.
Why the study?
Does surgical aortic valve replacement with the Carpentier-Edwards PERIMOUNT Magna Ease aortic valve with RESILIA tissue provide safe and effective outcomes in patients requiring AVR?
Does surgical aortic valve replacement with the Carpentier-Edwards PERIMOUNT Magna Ease aortic valve with RESILIA tissue provide safe and effective outcomes in patients requiring AVR?
The novel RESILIA tissue bioprosthetic aortic valve demonstrates excellent early safety, hemodynamics, and clinical effectiveness at 2 years post-surgical aortic valve replacement.
No takes yet. Share an insight, caveat, or question.
Supports early safety evaluation of RESILIA tissue in SAVR; leaves open durability and comparative efficacy questions.
Puskas et al. (2017) studied Surgical aortic valve replacement (n=689). Carpentier-Edwards PERIMOUNT Magna Ease aortic valve with RESILIA tissue was evaluated on 2-year actuarial freedom from mortality. Surgical aortic valve replacement with a novel bioprosthetic tissue (RESILIA) demonstrated excellent early safety, with a 2-year actuarial freedom from mortality of 94.3%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: